Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.07 USD | -0.10% | -3.98% | +14.40% |
May. 15 | Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital | MT |
May. 09 | X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise | MT |
Financials (USD)
Sales 2024 * | 509M | Sales 2025 * | 553M | Capitalization | 3.05B |
---|---|---|---|---|---|
Net income 2024 * | 341M | Net income 2025 * | 345M | EV / Sales 2024 * | 5.99 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.52 x |
P/E ratio 2024 * |
9.03
x | P/E ratio 2025 * |
9.41
x | Employees | - |
Yield 2024 * |
8.39% | Yield 2025 * |
8.67% | Free-Float | 98.08% |
Latest transcript on Hercules Capital, Inc.
1 day | -0.10% | ||
1 week | -3.98% | ||
Current month | -0.26% | ||
1 month | +6.00% | ||
3 months | +2.53% | ||
6 months | +22.32% | ||
Current year | +14.40% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Bluestein
CEO | Chief Executive Officer | 45 | 10-11-16 |
Seth H. Meyer
DFI | Director of Finance/CFO | 55 | 19-03-03 |
Kiersten Botelho
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gayle Crowell
BRD | Director/Board Member | 73 | 19-02-03 |
Robert Badavas
CHM | Chairman | 71 | 06-02-28 |
Director/Board Member | 61 | 23-09-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 19.07 | -0.10% | 811,232 |
24-05-15 | 19.09 | -1.14% | 1,167,312 |
24-05-14 | 19.31 | +1.15% | 1,044,647 |
24-05-13 | 19.09 | -4.07% | 1,646,112 |
24-05-10 | 19.9 | +0.20% | 1,540,640 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.40% | 3.05B | |
+12.82% | 1.77B | |
+8.43% | 1.51B | |
-11.54% | 1.2B | |
+11.49% | 737M | |
+28.93% | 552M | |
-4.17% | 503M | |
+29.04% | 480M | |
+3.90% | 309M | |
+73.27% | 321M |
- Stock Market
- Equities
- HTGC Stock